Frazier Life Sciences
Presença
Frazier Healthcare Partners possui 4 subsidiárias incluindo Comprehensive Pharmacy Services, Elevate Patient Financial Solutions e Frazier Life Sciences.
Eles estão dentro:
Fusão, aquisição e financiamento envolvendo Frazier Healthcare Partners.
Executivos
Veja o organograma con seus 23 executivos principais
Biografias mais buscadas da Frazier Life Sciences
- Albert Cha, Co-Managing Partner
- Patrick Heron, Co-Managing Partner
- James Topper, Co-Managing Partner
Recentes movimentos de executivos em Frazier Life Sciences
- Lauren Mifflin, ingressou na Companhia como Vice President of Company Creation (Notícia publicada em 1 de dezembro de 2023).
Recentes movimentos de executivos em Frazier Healthcare Partners
- Peter Tornatore, ingressou na Companhia como Vice President of Investor Relations (Notícia publicada em 30 de outubro de 2023).
Criar um alerta
para seguir os movimentos de executivos da Frazier Life Sciences.
Fundo
Frazier Healthcare Partners possui 1.482 concorrentes concorrentes Lloyds Development Capital (Reino Unido), BlackRock (Estados Unidos) e Vanguard (Estados Unidos).
Popular M&A news in Fundo
- Abrdn Private Equity Opportunities Trust mudará seu nome para Patria Capital Partners. (publicado em 30 de abril de 2024).
- HMC Capital adquiriu StratCap (publicado em 28 de fevereiro de 2024).
- Thomvest Ventures acaba de anunciar uma arrecadação de fundos de 250 milhões de dólares. (publicado em 17 de janeiro de 2024).
Outros contatos sugeridos na indústria do Fundo
- Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
- Mortimer Buckley - Chairman of the Board and Chief Executive Officer (retiring in Dec 2024) da Vanguard
- Jean-Marc Arbaud - President and Chief Executive Officer of CDPQ Infra da Caisse de Dépôt et Placement du Québec
Notícias
Últimos comunicados de imprensa de Frazier Life Sciences
- Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases | Diagonal Therapeutics
- Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline - Tubulis
- Applied Therapeutics Announces $100 Million Private Placement | Applied Therapeutics
- PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock | PepGen
- Frazier Life Sciences Strengthens Investment Team with Addition of Lin Mu, M.D., MBA as Senior Associate
- View more press releases Close
Redes sociais sobre Frazier Life Sciences
- Frazier Life Sciences na Wikipedia, Google News e Yahoo Finance
- Frazier Life Sciences na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Steve Bailey 
Ligue para a Frazier Life Sciences em +1 206...
